{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"CD4 lymphocytes decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Electrocardiogram QT corrected interval prolonged"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Investigations - Other, sodium decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Investigations - Other, potassium decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Investigations - Other, calcium increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Investigations - Other, Haemoglobin decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"Lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Weight increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"White blood cell decreased"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using Common Terminology Criteria for Adverse Events (CTCAE). grade 1 : mild, grade 2 : moderate, grade 3 : severe or medically significant but not immediately life-threatening grade, 4 : life threatening or disabling grade, 5 : death related to adverse event","groups":[{"description":"SyB L-0501: The administration of SyB L-0501 at 90 mg/m\\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.","id":"OG000","title":"SyB L-0501"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to around 44 weeks","title":"Number of Abnormalities (Grade ≥3) in Laboratory Test Values","type":"SECONDARY","unitOfMeasure":"Events"}